The Vaccine Company is a biotechnology company that is developing novel therapeutic vaccines for the treatment of leukemias and other cancers. The company's lead product is Proteinase 3 PR1 peptide vaccine, currently in clinical trials for the treatment of serious blood disorders – Acute Myeloid Leukemia (AML, Phase 3), Chronic Myeloid Leukemia (CML, Phase 2), and Myelodysplastic Syndrome (MDS, Phase 2). The company is also investigating other immunotherapies and novel approaches for the treatment of cancers.